Antiplatelet drugs and liver fibrosis
Liver fibrosis results from an imbalance between extracellular matrix formation and degradation. The background of liver fibrosis is chronic inflammation and subsequent microcirculation disturbance including microthrombosis. Platelets actively participate in liver fibrosis not only as a part of the...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-02-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2021.1883574 |
| _version_ | 1797684168471085056 |
|---|---|
| author | Pamela Czajka Adam Przybyłkowski Anna Nowak Marek Postula Marta Wolska Dagmara Mirowska-Guzel Anna Czlonkowska Ceren Eyileten |
| author_facet | Pamela Czajka Adam Przybyłkowski Anna Nowak Marek Postula Marta Wolska Dagmara Mirowska-Guzel Anna Czlonkowska Ceren Eyileten |
| author_sort | Pamela Czajka |
| collection | DOAJ |
| description | Liver fibrosis results from an imbalance between extracellular matrix formation and degradation. The background of liver fibrosis is chronic inflammation and subsequent microcirculation disturbance including microthrombosis. Platelets actively participate in liver fibrosis not only as a part of the clotting system but also by releasing granules containing important mediators. In fact, platelets may play a dual role in the pathophysiology of liver fibrosis as they are able to stimulate regeneration as well as aggravate the destruction of the liver. Recent studies revealed that antiplatelet therapy correlates with inhibition of liver fibrosis. However, liver impairment is associated with extensive coagulation disorders thus the safety of antiplatelet therapy is an area for detailed exploration. In this review, the role of platelets in liver fibrosis and accompanying hemostatic disorders are discussed. Additionally, results of animal and human studies on antiplatelet drugs in liver disorders and their potential therapeutic utility are presented. |
| first_indexed | 2024-03-12T00:25:35Z |
| format | Article |
| id | doaj.art-d79a7341f78e4644b1b1d165c22e1490 |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-12T00:25:35Z |
| publishDate | 2022-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-d79a7341f78e4644b1b1d165c22e14902023-09-15T10:38:09ZengTaylor & Francis GroupPlatelets0953-71041369-16352022-02-0133221922810.1080/09537104.2021.18835741883574Antiplatelet drugs and liver fibrosisPamela Czajka0Adam Przybyłkowski1Anna Nowak2Marek Postula3Marta Wolska4Dagmara Mirowska-Guzel5Anna Czlonkowska6Ceren Eyileten7Medical University of Warsaw, Center for Preclinical Research and Technology CEPTMedical University of WarsawMedical University of Warsaw, Center for Preclinical Research and Technology CEPTMedical University of Warsaw, Center for Preclinical Research and Technology CEPTMedical University of Warsaw, Center for Preclinical Research and Technology CEPTMedical University of Warsaw, Center for Preclinical Research and Technology CEPTInstitute of Psychiatry and NeurologyMedical University of Warsaw, Center for Preclinical Research and Technology CEPTLiver fibrosis results from an imbalance between extracellular matrix formation and degradation. The background of liver fibrosis is chronic inflammation and subsequent microcirculation disturbance including microthrombosis. Platelets actively participate in liver fibrosis not only as a part of the clotting system but also by releasing granules containing important mediators. In fact, platelets may play a dual role in the pathophysiology of liver fibrosis as they are able to stimulate regeneration as well as aggravate the destruction of the liver. Recent studies revealed that antiplatelet therapy correlates with inhibition of liver fibrosis. However, liver impairment is associated with extensive coagulation disorders thus the safety of antiplatelet therapy is an area for detailed exploration. In this review, the role of platelets in liver fibrosis and accompanying hemostatic disorders are discussed. Additionally, results of animal and human studies on antiplatelet drugs in liver disorders and their potential therapeutic utility are presented.http://dx.doi.org/10.1080/09537104.2021.1883574acetylsalicylic acidantiplatelet treatmenthepatocellular carcinomaliver fibrosisp2y12 inhibitorsplatelets |
| spellingShingle | Pamela Czajka Adam Przybyłkowski Anna Nowak Marek Postula Marta Wolska Dagmara Mirowska-Guzel Anna Czlonkowska Ceren Eyileten Antiplatelet drugs and liver fibrosis Platelets acetylsalicylic acid antiplatelet treatment hepatocellular carcinoma liver fibrosis p2y12 inhibitors platelets |
| title | Antiplatelet drugs and liver fibrosis |
| title_full | Antiplatelet drugs and liver fibrosis |
| title_fullStr | Antiplatelet drugs and liver fibrosis |
| title_full_unstemmed | Antiplatelet drugs and liver fibrosis |
| title_short | Antiplatelet drugs and liver fibrosis |
| title_sort | antiplatelet drugs and liver fibrosis |
| topic | acetylsalicylic acid antiplatelet treatment hepatocellular carcinoma liver fibrosis p2y12 inhibitors platelets |
| url | http://dx.doi.org/10.1080/09537104.2021.1883574 |
| work_keys_str_mv | AT pamelaczajka antiplateletdrugsandliverfibrosis AT adamprzybyłkowski antiplateletdrugsandliverfibrosis AT annanowak antiplateletdrugsandliverfibrosis AT marekpostula antiplateletdrugsandliverfibrosis AT martawolska antiplateletdrugsandliverfibrosis AT dagmaramirowskaguzel antiplateletdrugsandliverfibrosis AT annaczlonkowska antiplateletdrugsandliverfibrosis AT cereneyileten antiplateletdrugsandliverfibrosis |